31P Magnetic Resonance Spectroscopy Fructose Study

Healthy Clinical Trial

— 31PMRS_FRU  

Official title:

Investigating the Effects of an Oral Fructose Challenge on Hepatic ATP Reserves in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02217605
• Other study ID #: A32006_FRU
• Status: Completed
• Phase: N/A
• First received: August 12, 2014
• Last updated: August 14, 2014
• Start date: March 2011
• Est. completion date: December 2013

Study information

• Verified date: August 2014
• Source: University of Nottingham
• Contact: n/a
• Is FDA regulated: No
• Health authority: United Kingdom: National Institute for Health Research
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the effects of an oral fructose challenge on liver adenosine triphosphate (ATP) reserves using 31P magnetic resonance spectroscopy (MRS) as a potential measure measure of liver health.

Description:

This study uses 31P spectra acquired from the liver in healthy subjects following a fructose drink to monitor ATP levels. This is also related to baseline BMI, liver glycogen and liver lipid levels

Recruitment information / eligibility

• Status: Completed
• Enrollment: 10
• Est. completion date: December 2013
• Est. primary completion date: September 2013
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Male

• Age 18 - 30

• BMI 20 - 27 kg/m^2

• Healthy

Exclusion Criteria:

• Smokers

• Liver disease or Metabolic Disorders

• Metal implants (not suitable for MRI)

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Healthy

Intervention

Dietary Supplement:
• Fructose
Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast

Locations

Country	Name	City	State
United Kingdom	University of Nottingham	Nottingham	Nottinghamshire

Sponsors (3)

Lead Sponsor	Collaborator
Stephen Bawden	Biotechnology and Biological Sciences Research Council, Unilever R&D

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hepatic ATP reserves following an oral fructose challenge	Monitor hepatic ATP levels following an oral fructose challenge using 31P magnetic resonance spectroscopy	2 hours post prandial	No
Secondary	Correlate hepatic ATP depletion / recovery with BMI, liver lipids and liver glycogen	Measure baseline liver lipid and glycogen using magnetic resonance spectroscopy and correlate BMI, lipid and glycogen levels with rate of ATP depletion and recovery following an oral fructose challenge	2 hours post prandial	No